Bloomberg Law
April 10, 2017, 6:17 PM UTC

How Patent Trolls Sparked a Failed Assault on High Drug Prices

By Paul Barrett, Bloomberg Businessweek

Hedge fund manager Kyle Bass appears to be wrapping up a generally unsuccessful patent-law assault on drug manufacturers. “In the end, lobbying and special interests pay,” Bass told Bloomberg in a defeatist-sounding email. “Medicare and U.S. consumers pay the ultimate price for the evergreening of bad patents by the pharma cabal.”

As Bass retreats, it’s worth pausing to assess why his offensive, begun in early 2015, caused high anxiety in the drug industry.

A Bass-sponsored group called the Coalition for Affordable Drugs targeted 14 medicines, using a special procedure established by a 2012 patent-reform law. ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.